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Abstract
Purpose To explore the relationship between retinal fluid status and best-corrected visual acuity (BCVA) in patients treated 
with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) in the ALTAIR study.
Methods Outcomes were investigated according to overall fluid status at week 16 (predefined) and the relationship between any 
fluid, intraretinal fluid (IRF), subretinal fluid (SRF), or pigment epithelial detachment with BCVA at baseline, and weeks 16, 52, and 
96 (post-hoc). The analyses involved treatment-naïve patients (N = 246) with exudative age-related macular degeneration (AMD), 
aged ≥ 50 years with BCVA of 73–25 Early Treatment Diabetic Retinopathy Study letters, who participated in the ALTAIR study.
Results The mean (standard deviation) change in BCVA from baseline to week 52 was + 10.6 (10.9) and + 6.5 (16.0) letters in 
patients without and with fluid at week 16, respectively; and to week 96 was + 9.1 (14.3) and + 4.3 (16.1) letters in patients without 
and with fluid at week 16, respectively. The last injection interval was 16 weeks in 33.6% and 2.0% (week 52), and 62.9% and 17.6% 
(week 96) of patients without or with fluid at week 16, respectively. At baseline, 35.7% of patients had IRF and 85.2% of patients 
had SRF, which decreased to 11.8% (IRF) and 31.7% (SRF) of patients, 8.5% (IRF) and 18.7% (SRF), and 6.5% (IRF) and 20.7% 
(SRF) at weeks 16, 52, and 96, respectively. Presence of IRF at all timepoints was associated with poorer BCVA than if IRF was 
absent, while the presence of SRF was not associated with poorer BCVA compared with the absence of SRF.
Conclusion IVT-AFL T&E dosing was effective at clearing fluid regardless of fluid type in ~ 80% of patients with exuda-
tive AMD. Patients without fluid at week 16 had numerically better BCVA than those with fluid at week 16. Over 60% of 
patients without fluid at week 16 achieved the maximum treatment interval of 16 weeks by study end, compared with < 20% 
of patients with fluid at week 16. IRF (weeks 16, 52, 96), although evident in a small number of patients, was associated 
with poorer BCVA, whereas SRF was not.
Trial registration ClinicalTrials.gov Identifier: NCT02305238
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Key messages
Increasing evidence suggests that consideration of retinal fluid, and the role of the different fluid compartments, may be 
important in determining the impact of anti-vascular endothelial growth factor treatment on functional outcomes
in patients with exudative age-related macular degeneration 
Our analysis showed that an intravitreal-aflibercept treat-and-extend regimen, following initial monthly dos-
ing, was effective at clearing fluid and improving vision from Week 16 up to Week 96 in treatment-naïve pa-
tients with exudative AMD
Over 60% of patients without fluid at Week 16 achieved the maximum treatment interval of 16 weeks up to 
Week 96, and had numerically better best-corrected visual acuity compared with patients with fluid at Week 
16
Fluid compartment analysis demonstrated that intraretinal fluid was negatively associated with best-correct-
ed visual acuity, whereas subretinal fluid was not
Introduction
Exudative age-related macular degeneration (AMD) is char-
acterized by abnormal growth of new blood vessels in the 
macula [1] and is the leading cause of AMD-related vision 
loss [2]. Clinical management of exudative AMD involves 
administering anti-vascular endothelial growth factor (VEGF) 
agents, such as aflibercept and ranibizumab [1], with the aim 
of improving functional and anatomic outcomes. However, 
anti-VEGF treatments are associated with clinic and patient-
related burden, which can negatively impact long-term adher-
ence and lead to increased healthcare costs [3].
Treat-and-extend (T&E) is a proactive, individualized 
dosing strategy whereby the treatment interval is gradually 
extended or shortened based on physician decision regarding 
the maintenance of functional and anatomic stability [4]. 
The flexibility offered with the T&E approach minimizes 
the risk of overtreatment and undertreatment, thus reducing 
treatment burden and the risk for disease recurrence, 
while optimizing functional and anatomic outcomes [3]. 
Results of the ALTAIR study demonstrated that, following 
initial monthly dosing, intravitreal aflibercept (IVT-AFL) 
administered in a T&E dosing regimen was effective in the 
first year of treatment and was continuously efficacious in 
the second year in patients with exudative AMD in Japan 
[5]. In the ALTAIR study, the criteria for injection interval 
shortening, maintenance, or extension were based on 
functional and anatomic outcomes (central retinal thickness 
[CRT], total fluid, intraretinal fluid [IRF], subretinal fluid 
[SRF], neovascularization, and hemorrhage) [5].
Increasing evidence suggests that consideration of fluid, and 
the role of the different compartments, may be important in 
determining the impact of anti-VEGF treatment on functional 
outcomes in patients with exudative AMD [6–8]. An analysis from 
the Comparison of AMD Treatments Trials (CATT), in which 
patients with exudative AMD were randomized to receive treatment 
with ranibizumab or bevacizumab on a monthly or as-needed 
schedule, reported that, at all timepoints, eyes with residual IRF 
(especially foveal IRF) had worse mean visual acuity (VA) than 
those without IRF, whereas eyes with SRF had better VA than 
those without SRF [6]. However, the relationship between retinal 
fluid status and functional outcomes is not well understood, and 
determining the impact of compartmental changes on functional 
outcomes following anti-VEGF treatment could help to optimize 
patient management. Given the lack of consensus regarding the 
impact of fluid status on functional outcomes, predefined and post-
hoc analyses were conducted to explore baseline features that are 
potentially predictive of fluid status at week 16 and to investigate the 
relationship between overall retinal fluid status, fluid compartment 
type (IRF and SRF), and best-corrected visual acuity (BCVA) over 
96 weeks in patients treated with IVT-AFL using an individualized 
T&E dosing regimen in the ALTAIR study.
Methods
This article reports predefined and post-hoc explora-
tory analyses of data from ALTAIR, a 96-week, rand-
omized, open-label, phase 4 study (ClinicalTrials.gov, 
NCT02305238) that was conducted to investigate the 
efficacy and safety of repeated doses of IVT-AFL with 
two different T&E approaches in patients with exudative 
AMD [5]. ALTAIR was conducted at 41 sites across Japan 
between December 2014 and November 2017, in accord-
ance with the Declaration of Helsinki and the Interna-
tional Conference on Harmonization guidelines E6: Good 
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Clinical Practice. The protocol was approved by the inde-
pendent ethics committee or institutional review board at 
each study site. All patients provided written informed 
consent. As described in detail within the “Data analysis” 
section, the predefined analyses were conducted according 
to the presence or absence of fluid at week 16 and the pres-
ence or absence of fluid over time. The post-hoc analyses 
explored absolute BCVA by fluid status at each timepoint 
during the study.
Study design
The methodology of the ALTAIR study has been published 
previously [5]. Patients received 2 mg IVT-AFL injections at 
baseline, week 4, week 8, and week 16. At week 16, patients 
were randomized 1:1 to T&E with the treatment interval 
adjusted in either 2-week (IVT-AFL-2 W) or 4-week (IVT-
AFL-4 W) increments. Treatment intervals between IVT-
AFL injections were extended, maintained, or shortened 
based on predefined functional and anatomic criteria; and 
the minimum and maximum treatment intervals were 8 and 
16 weeks, respectively. The primary efficacy endpoint for the 
ALTAIR study was mean change in BCVA from baseline to 
week 52 [5]. Following the IVT-AFL injection at week 16, 
the timing of subsequent treatment visits was determined by 
the physician, based on predefined treatment criteria, at each 
visit. However, all patients were evaluated at weeks 52 and 
96, regardless of treatment schedule.
The ALTAIR study involved treatment-naïve 
adults ≥ 50 years of age with exudative changes due to 
active subfoveal choroidal neovascularization lesions sec-
ondary to AMD, including juxtafoveal lesions that affected 
the fovea, as evidenced by fluorescein angiography in the 
study eye. Patients had a BCVA of 73–25 Early Treatment 
Diabetic Retinopathy Study (ETDRS) letters (approxi-
mately 20/40–20/320 Snellen equivalent) in the study eye.
Study procedures
Data included in this analysis are based on optical coher-
ence tomography (OCT) assessments generated during 
the ALTAIR study to guide treatment decisions. The OCT 
images were subsequently assessed by the investigator and 
the results recorded. The present analysis utilizes data 
based on the investigator assessments recorded during the 
ALTAIR study, and a separate analysis of OCT images was 
not conducted. Investigators were required to use spectral-
domain OCT (SD-OCT; Supplementary Table 1) and the 
same machine was used throughout the study for follow-up 
of individual patients at each site.
Data analysis
The aim of the analyses was to explore the relationship 
between any fluid (defined by presence of IRF and/or SRF; 
not including sub-retinal pigment epithelium fluid), as well 
as individual fluid compartments (IRF or SRF), and BCVA. 
Baseline demographics and disease characteristics accord-
ing to fluid status at week 16 (with fluid/without fluid) were 
also explored.
These analyses comprise patients in the full analysis 
set (FAS; all randomized patients who received any study 
medication and had a baseline and ≥ 1 BCVA assessment 
after randomization [i.e., after week 16]); datasets for the 
IVT-AFL-2 W and IVT-AFL-4 W treatment arms were 
combined. The definitions of fluid used in the predefined 
analyses and the post-hoc analyses differed (as described 
in the “Predefined fluid analyses” and “Post-hoc analyses” 
sections). Statistical evaluation was performed using 
Statistical Analysis Software v9.4 (SAS Institute Inc., Cary, 
NC, USA).
Predefined fluid analyses
This analysis investigated overall fluid status on OCT 
assessment, defined as the presence or absence of any new 
or persistent fluid (remaining or increased fluid from the 
previous visit) at week 16. Treatment exposure, BCVA, and 
anatomic outcomes (mean change in BCVA and CRT) per 
week 16 fluid status were also explored, and 95% confidence 
intervals (CIs) were calculated. The proportion of patients 
with IRF and SRF was evaluated at each timepoint from 
baseline to week 96.
Post‑hoc analyses
Baseline demographics and disease characteristics 
per fluid status (presence or absence of fluid) at week 
16 were explored. A fluid compartment analysis was 
performed based on previously published methodology 
from CATT [6]. This analysis was designed to explore 
the relationship between any fluid (defined as IRF and/
or SRF), IRF, SRF, or pigment epithelial detachment 
(PED) with BCVA at any timepoint (mandatory study 
visits occurred at baseline and weeks 16, 52, and 96). 
Fluid status, defined as the presence or absence of new 
or persistent fluid (IRF and/or SRF), was assessed using 
OCT (as described previously). If fluid was present, the 
location of the fluid relative to the foveal center was 
recorded as foveal (within 500 µm of the foveal center), 
or non-foveal (beyond 500 µm of the foveal center). Due 
to the exploratory nature of these analyses, descriptive 
statistical evaluation was conducted.




All randomized patients in the ALTAIR study were included 
in these analyses (FAS, N = 246; IVT-AFL-2 W and IVT-
AFL-4 W treatment arms combined). Information on base-
line demographics and disease characteristics have previ-
ously been published [5]. Fluid status was unknown for 1 
patient who had been randomized to the IVT-AFL-2 W 
group. In the predefined analysis, no fluid was observed on 
OCT conducted by the study investigators at week 16 in 
58.1% (n = 148) of patients. In 41.5% (n = 102) of patients, 
the investigator noted presence of new or persistent fluid. 
Of patients without fluid at week 16, 85.3% and 84.6% had 
no fluid at weeks 52 and 96, respectively. Based on the pre-
defined analysis, no fluid was recorded in 4.1% (n = 10/244) 
of patients at baseline and 58.1% (n = 143/246), 68.7% 
(n = 169/246), and 67.5% (n = 166/246) of patients at weeks 
16, 52, and 96, respectively.
Treatment exposure per week 16 fluid status
Overall, from baseline to week 96, patients without and with 
fluid at week 16 received a mean (standard deviation [SD]) 
of 9.4 (1.7) and 11.8 (2.8) injections, respectively (Table 1). 
The mean (SD) last treatment interval at week 52 was 13.0 
(2.9) and 8.9 (1.8) weeks, and at week 96 was 14.1 (2.9) and 
9.9 (3.2) weeks in patients without and with fluid at week 
16, respectively. The last injection interval before week 52 
was ≥ 12 weeks in 67.1% (without fluid at week 16) and 
16.7% (with fluid at week 16) of patients and before week 
96 was ≥ 12 weeks in 82.5% (without fluid) and 25.5% (with 
fluid) of patients. The last injection interval before week 52 
was 16 weeks in 33.6% (without fluid at week 16) and 2.0% 
(with fluid at week 16) of patients and before week 96 was 
16 weeks in 62.9% (without fluid; Fig. 1A) and 17.6% (with 
fluid; Fig. 1B) of patients.
BCVA and anatomic outcomes per week 16 fluid 
status
At baseline, mean (SD) BCVA was 55.5 (12.4) and 54.5 
(12.8) letters for patients without and with fluid at week 
16, respectively. For patients without fluid at week 16, 
the mean (SD) change in BCVA from baseline to week 
52 was + 10.6 (10.9) letters, and to week 96 was + 9.1 
(14.3) letters. For patients with fluid at week 16, the 
mean change in BCVA was + 6.5 (16.0) letters and + 4.3 
(16.1) letters from baseline to weeks 52 and 96, respec-
tively (Fig. 2).
At baseline, mean (SD) CRT was 370.8 (137.9) µm and 
390.0 (145.1) µm for patients without and with fluid at 
week 16, respectively. For patients without fluid at week 
16, the mean (SD) change in CRT from baseline to week 52 
was − 132.0 (135.3), and to week 96 was − 134.5 (133.8) µm. 
For patients with fluid at week 16, the mean change in CRT 
was − 127.8 (138.9) and − 118.9 (144.4) µm from baseline 
to weeks 52 and 96, respectively (Fig. 3).
Baseline features per week 16 fluid status: 
a post‑hoc analysis
Post-hoc exploration of baseline features suggested that 
patients with a relatively thick CRT, a high PED height, 
who did not have polypoidal choroidal vasculopathy 
(PCV), or who did not have a subretinal hemorrhage were 
more likely to have retinal fluid at week 16 (Table 2). 
Mean (SD) baseline CRT was 370.8 (137.9) µm (patients 
without fluid at week 16) and 390.0 (145.1) µm (patients 
with fluid at week 16). At baseline, PED was observed in 
55.9% of patients without fluid at week 16 (mean PED 
height: 271.1 µm), compared with 78.4% of patients with 
fluid at week 16 (mean PED height: 341.4 µm). At base-
line, a total of 41.3% of patients had PCV among those 
without fluid at week 16, compared with 29.4% of those 
with fluid at week 16.
Fluid compartment analysis
In the predefined fluid compartment analysis, over 70% of 
patients had no new or persistent IRF or SRF at any meas-
ured timepoint after week 8 (Fig. 4). At baseline, 35.7% and 
Table 1  Treatment exposure (number of IVT-AFL injections) per 
week 16 fluid  statusa
Full analysis set (N = 246). All values are mean (SD)
a Fluid status was assessed by the investigator based on the presence 
of any new or persistent fluid (on OCT)
b Two adjustment groups are combined (IVT-AFL-2  W and IVT-
AFL-4  W); fluid status was unknown in the IVT-AFL-2  W adjust-
ment group (n = 1)
c Data are for weeks 52–96 in patients who were 52-week completers 
(without fluid [n = 135]; with fluid [n = 92])
IVT-AFL, intravitreal aflibercept; IVT-AFL-2  W, IVT-AFL 2-week 
adjustment; IVT-AFL-4 W, IVT-AFL 4-week adjustment; OCT, opti-
cal coherence tomography; SD, standard deviation
Without fluid at week 
16
(n =  143b)
With fluid 
at week 16
(n =  102b)
Baseline to week 96 9.4 (1.7) 11.8 (2.8)
  Baseline to week 52 6.6 (0.8) 7.6 (1.0)
  Week 52 to week  96c 3.0 (1.1) 4.7 (1.5)
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85.2% of patients had IRF or SRF, which had reduced by 
week 16 to 11.8% and 31.7% of patients for the respective 
fluid compartment.
BCVA according to fluid compartment: a post‑hoc 
analysis
In this post-hoc analysis, mean BCVA (ETDRS letters) 
was 57.1 at baseline (n = 16), 66.1 at week 16 (n = 149), 
65.4 at week 52 (n = 181), and 64.1 at week 96 (n = 179) 
for patients without any fluid (Fig. 5A).1 The presence 
of foveal IRF at all timepoints was associated with lower 
BCVA (ETDRS letters) than if IRF was absent (foveal 
IRF vs no IRF: 49.4 vs 57.5 at baseline; 57.5 vs 65.1 at 
week 16; 45.1 vs 65.3 at week 52; and 49.2 vs 63.9 letters 
at week 96). A similar trend was observed with non-foveal 
IRF compared with no IRF at baseline, week 16, and week 
52 (Fig. 5B). Conversely, the presence of foveal SRF was 
not associated with poorer BCVA (ETDRS letters) com-
pared with the absence of SRF (Fig. 5C). A similar trend 
was observed with non-foveal SRF compared with no 
SRF at all timepoints (Fig. 5C). Any adverse effects of 
the presence of foveal PED on BCVA (Fig. 5D) appeared 
to be relatively small (< 5 letters).
SRF was not associated with lower BCVA values, 
unless IRF was also present (defined as the presence or 
absence of IRF at week 52; data not shown). Overall, 33 
patients had new and/or persistent SRF both at weeks 
16 and 52. Of these, 30 patients did not have coexisting 
IRF at week 52, and, in this group, the mean BCVA was 
maintained from week 16 (65.5 letters [SD; range: 13.4; 
19.0–86.0]) to week 96 (64.1 letters [13.9; 19.0–83.0]). 
Of the 33 patients with new and/or persistent SRF both at 
weeks 16 and 52, 3 patients had coexisting IRF at week 
52, and, in this group, the mean BCVA decreased from 
week 16 (63.7 letters [4.0; 60.0–68.0]) to week 96 (51.3 
letters [1.5; 50.0–53.0]).
Discussion
In this predefined f luid analysis of data from the 
ALTAIR study, IVT-AFL T&E dosing was effective 
at clearing f luid and improving vision by week 16 in 
treatment-naïve patients with exudative AMD. The 
mean BCVA was similar between groups at baseline, 
and the mean change to week 52 was + 10.6 letters 
and + 6.5 letters in patients without and with f luid at 
week 16, respectively, with outcomes maintained to 
week 96. The mean change in CRT from baseline to 
week 96 followed a similar pattern; however, at base-
line, there was a slight difference between groups 
(370.8 µm and 390.0 µm in patients without and with 
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IVT-AFL-2 W adjustment (n=66)b
IVT-AFL-4 W adjustment (n=77)
Combined groups (n=143)c
Last interval up to 
Week 96, %
IVT-AFL-2 W IVT-AFL-4 W Combined
>8 weeks 90.9 87.0 88.8
≥12 weeks 83.3 81.8 82.5
16 weeks 62.1 63.6 62.9
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Last interval up to 
Week 96, %
IVT-AFL-2 W IVT-AFL-4 W Combined
>8 weeks 30.4 32.6 31.4
≥12 weeks 26.8 23.9 25.5
16 weeks 17.9 17.4 17.6
Last interval, mean (SD) 10.0 (3.3) 9.9 (3.1) 9.9 (3.2)
Weeks
B
IVT-AFL-2 W adjustment (n=56)b








Without fluid at week 16
With fluid at week 16
Fig. 1  The proportion of patients with a last treatment interval up to 
week 96 of 8, 10, 12, 14, or 16 weeks and mean (SD) last treatment 
interval in A patients without fluid at week 16 and B patients with 
fluid at week 16 according to IVT-AFL adjustment regimen in the 
full analysis set (N = 246).a,b,c The last treatment interval was calcu-
lated based on the last two doses received (overall, 227 patients com-
pleted week 52 of treatment and 212 patients completed week 96). 
aFluid status was assessed by the investigator based on the presence 
or absence of any new or persistent fluid (on OCT); bFluid status 
was unknown in the IVT-AFL-2  W adjustment group (n = 1); cTwo 
adjustment groups are combined (IVT-AFL-2 W and IVT-AFL-4 W). 
IVT-AFL, intravitreal aflibercept; IVT-AFL-2  W, IVT-AFL 2-week 
adjustment; IVT-AFL-4 W, IVT-AFL 4-week adjustment; OCT, opti-
cal coherence tomography; SD, standard deviation
1 Fluid refers to IRF and SRF compartments.
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treatment interval up to week 96, over 60% of patients 
without fluid at week 16 achieved the maximum treat-
ment extension interval of 16 weeks, compared with 
17.6% of patients with fluid at week 16. From baseline 
to week 96, patients without and with f luid at week 
16 received a mean of 9.4 and 11.8 injections of IVT-
AFL, respectively. The post-hoc evaluation of baseline 
features suggested that patients with relatively thinner 
CRT and a lower PED height at baseline were more 
likely to have no fluid at week 16. A higher proportion 
of patients without fluid at week 16 had PCV and sub-
retinal hemorrhage at baseline than those with fluid at 
week 16. Previous studies involving patients with PCV 
have reported comparable visual outcomes to those 
with typical AMD following treatment with IVT-AFL 
fixed or T&E dosing [9, 10]. This will be investigated 
further in future analyses.
Overall, the fluid compartment analysis showed that 
IVT-AFL T&E dosing was effective at clearing fluid 
in ~ 80% of patients with exudative AMD over the 96-week 
treatment period and led to improved BCVA, regardless 
of the fluid type. Over 70% of patients had no new or 
persistent IRF or SRF at any measured timepoint after 
week 8, following the three initial doses of IVT-AFL. The 
role of the different fluid compartments in determining the 
impact of anti-VEGF treatment on functional outcomes in 
patients with exudative AMD is a growing area of inter-
est [6–8]. In the CATT analysis, eyes with residual IRF 
(especially foveal IRF) had worse VA than those without 
IRF, whereas eyes with SRF had better VA than those 
without SRF [6]; findings were replicated at 2 and 5 years 
[7, 8]. In the 5-year CATT analysis, foveal IRF was inde-
pendently associated with worse VA over the course of 
the study, and patients with foveal SRF had better VA at 
5 years than those without SRF [8]. Findings from the 
present CATT-like post-hoc analysis add to the evidence, 
demonstrating that new or persistent foveal IRF, although 
evident in a small number of patients, was associated 
with lower BCVA. The reasons for the specific potential 
adverse impact of IRF on BCVA are not well understood, 
and suggestions include that intraretinal cystoid fluid may 
be a sign of a more aggressive lesion type as well as a sign 
of late presentation in chronic occult choroidal neovascu-
larization (CNV) [11]. IRF accumulates predominantly 
in the Henle fiber layer and the inner nuclear layer of the 
retina [12]. IRF likely results from damage to the outer 
blood–retinal barrier and to external limiting membrane 
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With fluid at Week 16 (n=102b)Without fluid at Week 16 (n=143b)




With fluid at 
Week 16
Baseline 55.5 (12.4) 54.5 (12.8)
Week 16 66.3 (13.5) 61.4 (14.3)
Week 52 66.1 (14.5) 61.0 (16.0)
Week 96 64.6 (17.1) 58.7 (17.4)
Fig. 2  Mean (SD) absolute and mean (95% CI) change in BCVA 
(ETDRS letters) from baseline to week 96 in patients without and 
with fluid at week  16a,b in the full analysis set (N = 246), with last 
observation carried forward. aFluid status was assessed by the investi-
gator based on the presence or absence of any new or persistent fluid 
(on OCT); bTwo adjustment groups are combined (IVT-AFL-2  W 
and IVT-AFL-4 W); fluid status was unknown in the IVT-AFL-2 W 
group (n = 1). BCVA, best-corrected visual acuity; CI, confidence 
interval; ETDRS, Early Treatment Diabetic Retinopathy Study; IVT-
AFL, intravitreal aflibercept; IVT-AFL-2  W, intravitreal aflibercept 
with 2-week adjustment; IVT-AFL-4  W, intravitreal aflibercept with 
4-week adjustment; OCT, optical coherence tomography; SD, stand-
ard deviation
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outer retinal layers, from photoreceptors through to the 
Henle fiber layer. Subsequent loss of photoreceptors could 
lead to decreased vision.
In our analysis, conducted in patients treated with IVT-
AFL, new or persistent SRF (foveal or non-foveal) was 
not associated with lower BCVA, consistent with previous 
reports [6–8]. However, the effect of persistent SRF on 
VA is unclear. In our further analysis, of the 33 patients 
with new and/or persistent SRF both at weeks 16 and 52, 3 
patients had coexisting IRF at week 52, and, in this group, 
the mean BCVA decreased from 63.7 letters (week 16) 
to 51.3 letters (week 96); however, because of the small 
number of patients, it is difficult to draw conclusions. 
The effects of coexisting IRF and SRF on BCVA remain 
unclear; therefore, further investigation is warranted.
The present analysis explored the relationship between 
fluid status at week 16 after initial dosing and BCVA fol-
lowing treatment with IVT-AFL in a T&E regimen over 
2 years, suggesting that absence of fluid at week 16 was 
predictive of good outcomes. In the ALTAIR study [5], 
patients received three initial monthly doses of IVT-AFL 
(weeks 0, 4, 8), and because week 16 was the last visit 
before randomization, it was the optimal timepoint to eval-
uate retinal fluid status following similar initial dosing in 
all patients. Onward from week 16 was considered to be 
the beginning of the maintenance phase of treatment with 
IVT-AFL. The positive impact of early reductions in retinal 
fluid with IVT-AFL treatment has been reported previously 
with a monthly dosing regimen in the VIEW trials. VA 
improvements from baseline in eyes with early persistent 
fluid were observed by week 16 and were maintained to 
week 52 with monthly injections of IVT-AFL. The pat-
tern of functional outcomes was similar regardless of fluid 
type (IRF or SRF) [13]. Approximately 60% of patients 
had their fluid resolved by week 16. While 40% of patients 
still had persistent fluid at this timepoint, > 30% of these 
patients had been able to extend treatment intervals beyond 
8 weeks. Further investigation is needed to understand the 
clinical relevance of persistent fluid in the respective com-
partments, and a differentiated approach to adapt treatment 
intervals should be formulated with the goal of maintaining 
improvements in visual function.
The main strength of this study was that the data 

























With fluid at Week 16 (n=102b)Without fluid at Week 16 (n=143b)
Mean (SD) CRT, µm Without fluid at Week 16
With fluid at 
Week 16
Baseline 370.8 (137.9) 390.0 (145.1)
Week 16 237.6 (56.4) 287.9 (87.8)
Week 52 238.3 (71.4) 262.1 (81.1)
Week 96 235.8 (64.6) 271.0 (87.9)
Fig. 3  Mean (SD) absolute and mean (95% CI) change in CRT (μm) 
from baseline to week 96 in patients without and with fluid at week 
 16a,b in the full analysis set (N = 246), with last observation carried 
forward. aFluid status was assessed by the investigator based on the 
presence or absence of any new or persistent fluid (on OCT); bTwo 
adjustment groups are combined (IVT-AFL-2 W and IVT-AFL-4 W); 
fluid status was unknown in the IVT-AFL-2 W group (n = 1). CI, con-
fidence interval; CRT, central retinal thickness; IVT-AFL, intravitreal 
aflibercept; IVT-AFL-2 W, intravitreal aflibercept with 2-week adjust-
ment; IVT-AFL-4 W, intravitreal aflibercept with 4-week adjustment; 
OCT, optical coherence tomography; SD, standard deviation
 Graefe’s Archive for Clinical and Experimental Ophthalmology
1 3
protocol, offering the opportunity to explore the relationship 
between fluid status and BCVA/anatomic outcomes in patients 
with exudative AMD. Furthermore, to our knowledge, this 
was the first CATT-like fluid analysis in patients treated with 
IVT-AFL. We should acknowledge that the CATT analysis 
identified various other factors (e.g., presence of subretinal 
hyper-reflective material, thinner retina, and greater CNV 
lesion area [8]) as being independently associated with 
BCVA loss. It was not possible to investigate these in our own 
analysis; however, the relationship between fluid and BCVA 
is valid despite the potential contributions of other drivers.
A limitation of these analyses was the differing defi-
nitions of fluid between the predefined analysis, which 
was based on the presence or absence of new or persis-
tent fluid, and the post-hoc analysis, which was based 
on the presence or absence of any fluid (specifically IRF 
and/or SRF). Furthermore, the original study was not 
designed to determine the relationships between com-
partment fluid status and impact of disease outcomes 
after IVT-AFL treatment, and as the specific volume of 
fluid was not evaluated, quantitative fluid analysis could 
not be conducted. Limitations in relation to SD-OCT 
techniques and SD-OCT scan analysis for the determina-
tion of fluid status must also be acknowledged. Although 
there was no reading center involved in the ALTAIR 
study, SD-OCT machine and image settings for OCT 
were the same throughout the study at each site. The 
SD-OCT images were not read by the same observer 
nor were they checked by another individual, but were 
guided by a specific OCT manual.
Table 2  Baseline features per 
week 16 fluid  statusa
Full analysis set (N = 246). All values are mean (SD) unless otherwise stated
a Fluid status was assessed by the investigator based on the presence of any new or persistent fluid (on 
OCT)
b Two adjustment groups are combined (IVT-AFL-2 W and IVT-AFL-4 W); fluid status was unknown in 
the IVT-AFL-2 W group (n = 1)
c Some patients were diagnosed as 1 or 2 subtypes
d Missing (n = 1)
e Unknown for patients without fluid (n = 1) and with fluid (n = 2)
f Missing (n = 2), unknown (n = 3)
g Missing (n = 2)
AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; CNV, choroidal neovasculari-
zation; CRT , central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; FA, fluores-
cein angiography; IRF, intraretinal fluid; PCV, polypoidal choroidal vasculopathy; PED, pigment epithelial 
detachment; RAP, retinal angiomatous proliferation; SRF, subretinal fluid
Without fluid at week 16
(n =  143b)
With fluid at week 16
(n =  102b)
Age, years 74.3 (8.2) 73.6 (7.9)
Male, n (%) 102 (71.3) 75 (73.5)
BCVA, ETDRS letters 55.5 (12.4) 54.5 (12.8)
CRT, µm 370.8 (137.9) 390.0 (145.1)
Type of AMD,c n (%)
  Typical AMD 80 (55.9) 70 (68.6)
  PCV 59 (41.3)d 30 (29.4)d
  RAP 9 (6.3)d 4 (3.9)d
Type of CNV lesions on FA,e n (%)
  Classic 51 (35.7) 26 (25.5)
  Classic and occult 20 (14.0) 11 (10.8)
  Occult 70 (49.0) 63 (61.8)
  No CNV 1 (0.7) 0 (0.0)
IRF, n (%) 54 (37.8)f 33 (32.4)
SRF, n (%) 116 (81.1)g 91 (89.2)
PED, n (%) 80 (55.9)g 80 (78.4)
Mean height of PED, µm 271.1 (179.2) 341.4 (266.8)
Mean width of PED, µm 2293.1 (1231.5) 2370.1 (1553.9)
Subretinal hemorrhage, n (%) 72 (50.3)d 33 (32.4)g
Intraretinal hemorrhage, n (%) 39 (27.3)d 19 (18.6)g
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In conclusion, this analysis of data from the ALTAIR 
study demonstrated that IVT-AFL T&E dosing was 
effective at clearing fluid in over 70% of treatment-naïve 
patients with exudative AMD and improving vision. 
Findings from the predefined analysis demonstrated that 
patients without fluid had better BCVA than those with 
fluid at week 16. In patients with exudative AMD, base-
line features such as CRT and PED height may play a 
role in determining the initial response of retinal fluid to 
treatment with IVT-AFL; further research is required to 
investigate predictive factors for response. The post-hoc 
analysis showed that IRF, although evident in a small 
number of patients, was associated with lower BCVA, 
whereas foveal SRF was not. Further quantitative analyses 





















































Fig. 4  The proportion of patients with A IRF or B SRF at each time-
point from baseline to week  96a,b in the full analysis set (N = 246), 
with last observation carried forward. aFluid status was assessed 
by the investigator based on the presence or absence of any new or 
persistent fluid (on OCT); bTwo adjustment groups are combined 
(IVT-AFL-2  W and IVT-AFL-4  W); IRF and SRF fluid status was 
unknown in n = 2 at baseline and in n = 5 at week 8. IRF, intrareti-
nal fluid; IVT-AFL, intravitreal aflibercept; IVT-AFL-2  W, intravit-
real aflibercept with 2-week adjustment; IVT-AFL-4  W, intravitreal 
aflibercept with 4-week adjustment; OCT, optical coherence tomogra-



























































































































Fig. 5  Mean absolute BCVA (ETDRS letters) and 95% confidence 
intervals at mandatory study visits at weeks 0, 16, 52, and 96 in A 
patients without or with any foveal or non-foveal fluid,a B patients 
without or with any foveal or non-foveal IRF, C patients without or 
with any foveal or non-foveal SRF, and D patients without or with 
any foveal or non-foveal PED in the full analysis set (N = 246).b,c The 
number underneath each bar represents the number of patients in each 
group at each study visit. aIncludes IRF and SRF only; bMissing for 
each fluid compartment (n = 2); cUnknown for IRF (n = 3). BCVA, 
best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retin-
opathy Study; IRF, intraretinal fluid; PED, pigment epithelial detach-
ment; SRF, subretinal fluid
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